



Arizona Board of Pharmacy Office
1616 W. Adams, Suite 120
Phoenix, AZ 85007
Telephone (602) 771-2727 Fax (602) 771-2749
www.AZPharmacy.gov

**NOTICE AND AGENDA OF CSPMP TASK FORCE MEETING
AT THE ARIZONA STATE BOARD OF PHARMACY**

Pursuant to A.R.S. § 38-421.02, notice is hereby given to the members of the Arizona State Board of Pharmacy (Board) and to the general public that the Board will hold a regular meeting open to the public on:

Date(s):

November 7, 2018: 8:30 am to 10:30 am
(CSPMP TASK FORCE MEETING)
(No C.E. Credit will be issued)

Location:

Arizona State Board of Pharmacy Office
1616 W. Adams, First Floor Board Room
Phoenix, AZ 85007

One or more members of the Board may participate in the meeting by Telephone.

Title 2 of the Americans with Disability Act (ADA) prohibits the Board from discriminating on the basis of disability in its public meetings. Persons with a disability may request a reasonable accommodation by contacting the Board Office at 602-771-2727. Requests should be made as early as possible to allow time to arrange the accommodation.

During the course of the meeting, the Board, upon a majority vote of a quorum of the members, may hold an executive session for the purposes of obtaining legal advice from the Board's attorney on any matter listed on the agenda pursuant to A.R.S. § 38-431.03 (A)(3) and may hold an executive session on agenda items for the purpose of discussion or consideration of confidential materials pursuant to A.R.S. § 38-431.03 (A)(2). The executive session will be held immediately after the vote and will not be open to the public.

The agenda is subject to change up to 24 hours prior to the meeting. The Board president reserves the right to change the order of the items on the agenda, except for matters set for a specific time.

AGENDA – Wednesday, November 7, 2018

The agenda for the meeting is as follows:

1. Call to Order – Michael Blair – Chairperson.

a. Purpose

Establish a task force of healthcare professionals, licensing boards, Board of Pharmacy, Arizona Department of Health Services, and law enforcement agencies to identify specific improvements that should be made to enhance the Arizona Controlled Substances Prescription Monitoring Program (CSPMP). Considerations should include but are not limited to:

- i. Potential need for grant funding and/or technical assistance to assist health care providers to link their electronic health records to the CSPMP
- ii. Additions to CSPMP to flag patients at higher risk of overdose
- iii. Additions to CSPMP to flag patients who exhibit drug diverting behaviors
- iv. Addition of veterinarians to reporting into and checking the CSPMP
- v. Assessment of exemptions from mandate to check the CSPMP
- vi. Improvement to prescriber report cards
- vii. Use of CSPMP as a public health surveillance tool

2. Introduction of all participants.

Task Force Members:	
Board of Pharmacy	Michael Blair
Medical Board	Pat Mcorley
AZ Osteopathic Board	Amber Brake
AZ Medical Association	Ingred Garvey
AHCCCS	Shana Malone
ADHS	Sheila Sjolander
Arizona Pain Society	Stephen Borowsky
AAG	Matthew Williams
AAG	Travis Williams / Ron Davis
DEA	Julie Antilla
AzPA	Kelly Fine
Board of Pharmacy	Kam Gandhi
Board of Pharmacy	Douglas Skvarla
Hospital Associations	Jennifer Carusetta
Hospital Associations	Debbie Johnston
Arizona Pain Society leadership	Dr. Julian Grove
Arizona Society of Interventional Pain Physicians	Dr. Bill Thompson
Arizona Association of Health Plans	Deb Gullet

Arizona Osteopathic Association	Pete Wertheim
Arizona Retailers Association	Michelle Ahlmer
Banner Health	Ayrn O'Connor
Arizona Pain Doctors	Pat Hogan
Lobbyist	John Thomas

3. Recap of Opioid Epidemic Act

- No more prescriber dispensing of CII opioids
- 5 day limit on initial opioid prescription
- Max of 90 MME/day
- Mandatory RPh checking of PMP for CII medications
- Red Caps on all CII opioids
- Mandatory e-prescribing of CII opioids

4. CSPMP Achievements

- See attachment

5. 2019 EPCS Mandate

- EPCS Basics attachment
- Waiver forms available at pharmacy.az.gov (see attachment)

6. Pharmacists Navigating Corresponding Responsibility During the Opioid Epidemic

- Discussion Panel
- See DEA attachment about Corresponding Responsibility

7. Post-surgical Prior Authorizations/ Overrides

8. Potential CSPMP Technological Improvements

- See Attachment

99. Call to the Public

The Board may make an open call to the public during the meeting, subject to reasonable time, place and manner restrictions, to allow individuals to address the Board on any issue(s) within its jurisdiction. Pursuant to A.R.S. §38-431.91 (G), members of the Board are not allowed to discuss or take legal action on matters raised during an open call to the public unless the matters are properly noticed for discussion and legal action. However, the Board may ask staff to review the matter or may ask that the matter be placed on a future agenda.